Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 0 study of Veyonda in healthy volunteers

Trial Profile

A phase 0 study of Veyonda in healthy volunteers

Phase of Trial: Phase 0

Latest Information Update: 29 Oct 2018

At a glance

  • Drugs Idronoxil (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Oct 2018 New trial record
    • 22 Oct 2018 According to a Noxopharm media release, the company is planning to initiate this IND-enabling Phase 0 study in Q1 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top